1. Home
  2. BSL vs CRBU Comparison

BSL vs CRBU Comparison

Compare BSL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

N/A

Current Price

$12.93

Market Cap

172.0M

Sector

Finance

ML Signal

N/A

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$1.86

Market Cap

192.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BSL
CRBU
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
192.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BSL
CRBU
Price
$12.93
$1.86
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
40.2K
1.9M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
9.55%
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.45
$1.04
52 Week High
$14.35
$3.53

Technical Indicators

Market Signals
Indicator
BSL
CRBU
Relative Strength Index (RSI) 39.42 39.30
Support Level $12.82 $1.75
Resistance Level $12.98 $2.02
Average True Range (ATR) 0.11 0.16
MACD -0.02 -0.04
Stochastic Oscillator 27.03 2.31

Price Performance

Historical Comparison
BSL
CRBU

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: